Proposed Pharmacoeconomics Guideline p to Saudi Food & Drug ...

More documents

Recommendations

Info

International ti lE ExperienceHjelmgren et al report agreement on 75% of methodologicalprinciplesi The main differences are in guidance on:– study perspective (e.g. inclusion of non-healthcarecosts)– economic outcomes (e.g. QALYs, WTP)– handling uncertaintyValue in Health 2001,4:225-250
Why do guidelines differ?• Some important differences in national perspective (e.g.views on equity in healthcare)• Methods develop over time• <strong>Guideline</strong>s reflect the views of those who develop them,which may or may not reflect the wider consensus• Some guidelines may contain methodological errors
Page 1 and 2: Proposed Pharmacoeconomics Guidelin
Page 3 and 4: Situations where economic evaluatio
Page 5 and 6: International Experiencee • Sever
Page 7: International ExperienceReimburseme
Page 11 and 12: Primary AudienceSaudi decision and
Page 13 and 14: Standard Reporting Format• A stru
Page 16 and 17: Executive Summary• The Executive
Page 18 and 19: 2. BACKGROUND• General comments o
Page 20 and 21: 4. METHODS4.1 Perspective- State an
Page 22 and 23: 4. METHODS cont.4.6 Outcome measure
Page 24 and 25: 4. METHODS cont.4.8 Modelling- Econ
Page 26 and 27: 4. METHODS cont.4.10 Time horizon-
Page 28 and 29: 5. RESULTS cont5.2 Results of varia
Page 30 and 31: 7. CONCLUSIONS• Address the resea

Proposed Pharmacoeconomics Guideline p to Saudi Food & Drug ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?